Cognition Therapeutics Files 8-K

Ticker: CGTX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1455365

Cognition Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyCognition Therapeutics INC (CGTX)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, regulation-fd

Related Tickers: COGT

TL;DR

COGT filed a routine 8-K, no major news.

AI Summary

Cognition Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates standard corporate reporting activity for Cognition Therapeutics, Inc. It does not disclose new material information that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain any new material information or significant financial disclosures.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is January 13, 2025.

In which state was Cognition Therapeutics, Inc. incorporated?

Cognition Therapeutics, Inc. was incorporated in Delaware.

What is the address of Cognition Therapeutics, Inc.'s principal executive offices?

The address of Cognition Therapeutics, Inc.'s principal executive offices is 2500 Westchester Avenue Purchase, NY 10577.

Does this filing disclose any specific new financial results or material events?

No, this filing is a standard 8-K reporting a Regulation FD Disclosure and Financial Statements and Exhibits, and does not appear to disclose specific new financial results or material events beyond routine reporting.

Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-13 11:55:25

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that Cognition Therapeutics, Inc. may use from time to time in presentations or discussions with investors, analysts, and other parties. The information in this Item 7.01 (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Investor presentation of Cognition Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing